DXCM Stock DexCom, Inc.
US · NasdaqGSLast in our picks 2026-10-24 — not in the current list; analysis below is from that screen
Continuous glucose monitoring expansion supports durable growth and improving international penetration.
Future value: $96.46 (+23.76%) · 6-12 months · analyst consensus
Signal breakdown
- ▸Above-sector growth forecasts and consensus target imply meaningful upside.
- ▾Below 50-day MA (-10.23%)
- ▸Above 200-day MA — long-term uptrend
- ▸~24% upside to price target
Is DXCM a buy right now?
Trend: DXCM is trading below the 50-day average (-9.27%), RSI 48 — neutral momentum, with a 3-month return of +4.97%.
Valuation & quality: DexCom, Inc. trades on a trailing P/E of 31.2, forward P/E 25.2, PEG 1.29, price-to-book 11.31; fundamentals show net margin 20.1%, return on equity 38.5%, revenue growth 13.1% year on year.
Analyst consensus: 26 analysts have a mean 12-month price target of $96.19 (+22.4% vs the last close; range $79.00 – $115.00), consensus rating “strong buy”.
Our screen: STRONG BUY (score 4) — Continuous glucose monitoring expansion supports durable growth and improving international penetration.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -14.50% | -5.20% | +23.80% | -8.70% | +23.90% | +9.10% | -5.20% | -8.90% |
Fundamentals
Analyst price target
Technical signals
About DexCom, Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Sector: Healthcare · Industry: Medical Devices · United States · 11,000 employees · Website
Related Health Care picks
Browse: all US stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.